There are more than a thousand publicly traded healthcare companies on US exchanges alone. Globally, hundreds more are listed on the LSE, Euronext, and exchanges across Asia-Pacific. Together they represent...
The branded cardiovascular market is forecast to grow at 11% a year between 2025 and 2032, well ahead of the 7% forecast for prescription drugs overall. That growth is fueled...
We’re always delighted to welcome new people into the fold at Evaluate, particularly when they bring a new perspective on a critical part of the life sciences market. Today’s subject...
As a biotech approaches commercial launch, the forecast often still carries the shape it was given in the early days: built by finance, before a commercial team existed. In this...
Most people in pharma are aware that R&D costs are rising, both in dollar terms and in development timelines. But the reaction is less well-known: risk is being front loaded...
Immunology is one of pharma’s most valuable and fastest-growing therapy areas, with forecast compound annual growth of over 9% and anticipated combined sales of $200 billion by 2032. Multi-indication immunology...
